A webcast of the fireside chat will be accessible online by visiting the events and presentations page under the investors section of Angion’s website at https://ir ...

UNIONDALE, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a biopharmaceutical company focused on the discovery, development, and commercialization of novel small ...

For sale: one biotech, badly damaged. So starts what could be the final chapter in the story of Angion Biomedica. Weeks after halting a study over a potential safety signal, the biotech has decided to ...

Angion Biomedica announced positive phase II clinical trial results for its drug ANG-3777, which treats acute kidney injuries. The study tested whether the small molecule could help kidney transplant ...

In a merger with troubled Angion Biomedica, Elicio Therapeutics has spied an opportunity to finally list on the Nasdaq as it prepares to push a cancer vaccine into phase 2 trials. The writing had been ...

Angion Biomedica (NASDAQ: ANGN) will be changing to (NASDAQ: ELTX) at the open this morning. This is all a part of the merger with Elicio Therapeutics from January - with an assist from a little stock ...

Angion Biomedica (ANGN) stock has had a difficult run since the company's shares leapt in initial trading after its IPO on Feb. 9, which raised $92m via the issuance of 5.75m shares at a price of $16.

Cancer immunotherapy developer Elicio Therapeutics is finally getting a listing on the public markets to finance its clinical research. But rather than the traditional IPO it had been seeking, the ...

Angion Biomedica ended 2022 in the midst of a strategic review after its lead drug for kidney diseases flamed out, and it has now charted a path forward – a reverse merger with clinical-stage biotech ...

ST. GALLEN, Switzerland & UNIONDALE, NY--(BUSINESS WIRE)--Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN) today announced that the ...

UNIONDALE, N.Y., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...

UNIONDALE, N.Y.--(BUSINESS WIRE)--Angion Biomedica Corp. announced today that it plans to commence enrollment of a Phase 3 clinical trial using its investigational drug BB3 to treat delayed graft ...